Cannabidiol (CBD) is being infused into a growing list of products, from foods to pharmaceutical medications. One of the most promising sectors for CBD is cosmetics, with CBD-infused cosmetic products becoming increasingly common in global markets, particularly in Europe.

Unfortunately, the European Union’s insufficient regulations regarding CBD cosmetics have resulted in companies experiencing considerable uncertainty. The European Union is currently seeking public input via a public consultation for CBD-infused cosmetics, which may lead to a more modernized approach to CBD cosmetics regulation.

“The European Union has launched a public consultation on the preliminary opinion of the Scientific Committee on Consumer Safety (SCCS) regarding the use of cannabidiol (CBD) in cosmetic products. The deadline for submitting technical comments and data is January 21, 2026.” reported DolceVita in its original coverage (translated from Italian to English).

“Industry professionals still have a week to submit their opinions on what promises to be a key step that could define the rules, limits, and future of CBD cosmetics in Europe.” the outlet also reported.

The SCCS is specifically seeking input to help determine “the maximum concentration of Cannabidiol that is considered safe when used in cosmetic products.” According to the public consultation listing, “the SCCS considers the presence of THC impurities as safe at concentrations up to 0.00025% in dermal and oral cosmetic products.”

“The global CBD Skincare Market is poised for rapid expansion, with forecasts revealing a compound annual growth rate (CAGR) of 15.76% from 2025 to 2030.” analysts at Research and Markets previously stated.

A team of researchers affiliated with various academic universities in India and Australia recently examined the efficacy of nanoformulated cannabidiol as a treatment for serious skin conditions and wound care. Their findings were published in the European Journal of Pharmaceutics and Biopharmaceutics.

“Applications for acne, psoriasis, and eczema show enhanced patient compliance and efficacy. Despite clinical and regulatory obstacles, nano-CBD platforms provide a safe, focused, and efficient approach to improving dermatological care.” the researchers concluded.